Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Error message

    • Deprecated function: Return type of DatabaseStatementBase::execute($args = [], $options = []) should either be compatible with PDOStatement::execute(?array $params = null): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2246 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).

    Jennifer Smith

    Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.

    News

    Liquid vs. tissue biopsy in advanced prostate cancer: Why not both?

    Author:
    Jennifer Smith
    Publish date: February 12, 2021

    A large study showed similar results with liquid and tissue biopsies while also revealing strengths and...

    • Read More

    News

    Combo disappoints in metastatic, castration-resistant prostate cancer

    Author:
    Jennifer Smith
    Publish date: February 11, 2021

    Adding saracatinib to docetaxel increased toxicity without improving efficacy.

    • Read More

    News

    Treatments linked to death in COVID patients with thoracic cancers

    Author:
    Jennifer Smith
    Publish date: June 29, 2020

    Prior treatment with steroids, anticoagulants, chemotherapy alone, or chemo plus immunotherapy were all associated with an increased risk of death...

    • Read More

    News

    Nivolumab approved to treat esophageal squamous cell carcinoma

    Author:
    Jennifer Smith
    Publish date: June 11, 2020

    Nivolumab is approved for use in previously treated, unresectable, advanced, recurrent, or metastatic esophageal...

    • Read More

    News

    Frontline nivo-ipi plus chemo approved for metastatic NSCLC

    Author:
    Jennifer Smith
    Publish date: May 27, 2020

    The combination of nivolumab, ipilimumab, and platinum-doublet chemotherapy is approved as frontline treatment...

    • Read More

    News

    FDA approves brigatinib and companion diagnostic for NSCLC

    Author:
    Jennifer Smith
    Publish date: May 27, 2020

    The FDA approved brigatinib to treat adults with ALK-positive metastatic non–small cell lung cancer and approved...

    • Read More

    News

    FDA expands approval of atezolizumab in NSCLC

    Author:
    Jennifer Smith
    Publish date: May 20, 2020

    Atezolizumab is approved as first-line monotherapy for adults with metastatic non–s...

    • Read More

    News

    FDA approves olaparib/bevacizumab maintenance

    Author:
    Jennifer Smith
    Publish date: May 11, 2020

    The FDA has approved a new indication for olaparib and a companion diagnostic for adults with advanced...

    • Read More

    News

    NSCLC: FDA approves capmatinib and companion assay

    Author:
    Jennifer Smith
    Publish date: May 6, 2020

    Capmatinib is the first FDA-approved treatment for NSCLC with MET exon 14 skipping mutations.

    • Read More

    News

    Antitumor treatment may increase risk of severe events in COVID-19 patients

    Author:
    Jennifer Smith
    Publish date: May 1, 2020

    Receiving antitumor treatment within 14 days of COVID-19 diagnosis was linked to a higher risk of ICU admission...

    • Read More

    News

    Metastatic cancer linked to worse outcomes of COVID-19

    Author:
    Jennifer Smith
    Publish date: April 29, 2020

    Patients with hematologic malignancies or metastatic cancers had particularly high risks of developing severe or...

    • Read More

    News

    Mitomycin approved for low-grade upper tract urothelial cancer

    Author:
    Jennifer Smith
    Publish date: April 15, 2020

    The FDA’s fast-track approval of mitomycin is based on results from the phase 3 OLYMPUS trial.

    • Read More

    News

    Barriers to clinical trial participation revealed by gynecologic cancer patients

    Author:
    Jennifer Smith
    Publish date: March 31, 2020

    A survey suggests a lack of discussion about clinical trials between doctors and patients with gynecologic cancers.

    • Read More

    News

    Doublet may be beneficial in wild-type, advanced NSCLC

    Author:
    Jennifer Smith
    Publish date: March 19, 2020

    About 77% of patients achieved a partial response or had stable disease on combination apatinib and vinorelbine.

    • Read More

    News

    Drug reduces oral mucositis without affecting tumor control

    Author:
    Jennifer Smith
    Publish date: March 10, 2020

    Locoregional control, distant metastasis, and survival rates were similar in patients who received the drug, GC4419, and those who did not.

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2023 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery